Global PBMCs Market to Surpass USD 729 Million by 2032 on the Back of Cell-Based Therapy Boom and Immunology Research Growth

Cleveland Street, VA, United States, July 25, 2025 – The global peripheral blood mononuclear cells (PBMCs) market is expected to reach USD 729.21 million by 2032, growing at a CAGR of 10.09% during the forecast period 2025–2032, according to Markets and Data. The market is witnessing global demand for immune cell research materials and robust expansion driven by the increasing adoption of PBMCs in cell-based therapies, next-gen vaccine development, and immunology research, as well as growing demand for reliable biospecimens in drug discovery and clinical trials.

PBMCs, critical in translational research medicine, immune profiling tools, and regenerative therapies are seeing expanded use among pharmaceutical companies, contract research organizations (CROs), and academic institutions. The scalability, viability, and transportability of cryopreserved PBMCs are further propelling market growth for cryopreserved cells for international clinical. Emerging applications in CAR-T therapy, autoimmune disease research, and infectious disease modeling continue to boost demand.

“The shift toward precision medicine, advanced immunotherapies, and high-throughput clinical research has elevated PBMCs as an essential biospecimen for innovation. This market reflects the growing need for reproducible, high-quality cellular therapeutic materials to support complex therapeutic development,” said Vivek Gupta, SVP, Markets & Data.

Click Here To Get Full Analysis Report: https://www.marketsandata.com/industry-reports/peripheral-blood-mononuclear-cells-market

Key Market Trends and Drivers

• Expanding Cell-Based Therapies: Rising investment in regenerative medicine, CAR-T therapies, and next-gen vaccines is driving the need for PBMCs in early-stage R&D and clinical manufacturing.
• Biobanking and Cryopreservation Demand: Cryopreserved PBMCs dominate the product segment due to their extended shelf life, high viability, and compatibility with automated storage and distribution systems.
• Growth in Immunology Research: The rise in autoimmune diseases, cancer immunotherapies, and infectious disease studies is fueling PBMC adoption across preclinical and clinical pipelines.
• Evolving Isolation Technologies: While density gradient centrifugation remains the industry standard for routine isolation, adoption of leukapheresis in cell therapy programs is emerging for large-scale therapeutic applications.

Cryopreserved PBMCs remain the preferred biospecimen due to their stability and scalability in multi-center studies. There is a growing trend in biospecimen usage for drug discovery as they are widely used across large pharmaceutical companies and CROs for their consistency in high-throughput human cell-based assays for immunotherapy research. Among techniques, density gradient centrifugation leads due to its simplicity and reliability, while leukapheresis continues gaining traction in cell therapy research.

By source, human PBMCs dominate due to their relevance in disease modeling and therapeutic development. Animal-derived PBMCs remain vital for foundational and preclinical research, particularly in comparative immunology.

Regional Highlights

North America maintains the largest share of the global PBMCs market, supported by a mature research ecosystem, robust clinical trial infrastructure, and advanced biobanking networks. Asia-Pacific is witnessing rapid growth, fueled by rising healthcare investments, global research collaborations, and an evolving biomanufacturing landscape.

Competitive Landscape and Strategic Developments

Leading players such as Lonza Group AG, Charles River Laboratories, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., and BioIVT LLC are heavily investing in advanced isolation, cryopreservation, and cell storage systems & technologies. Strategic partnerships and acquisitions continue shaping the competitive landscape.

In June 2025, iXCells Biotechnologies USA, Inc. introduced its modular iPSCore platform, which uses PBMCs as source material to generate highly characterized iPSC-derived human cell models. With over 1,000 samples processed annually, the platform is positioned to scale the production of patient-specific cell lines by 2026. This will further expand PBMC market growth in pharmaceutical and role of PBMCs in personalized medicine pipelines.

Download Free Sample Report

Report Coverage

The newly released report titled Global Peripheral Blood Mononuclear Cells Market Assessment, Opportunities and Forecast, 2018–2032F by Markets and Data offers:

·         Market size, growth trends, and CAGR projections

·         In-depth segmentation by product, application, techniques, source, and region

·         Company profiles and strategic benchmarking

·         Pricing trends, margin analysis, and investment outlook

·         Competitive landscape and M&A developments

·         Regional analysis of cell isolation market trends

Markets and Data is a global research and consulting firm delivering market intelligence across healthcare, biotechnology, manufacturing, infrastructure, and technology sectors. The firm provides data-driven insights to support strategic investment and innovation across emerging and established markets.

Contact

Mr. Vivek Gupta

5741 Cleveland street,

Suite 120, VA beach, VA, USA 23462

Tel: +1 (757) 343–3258

Email: info@marketsandata.com

Website: https://www.marketsandata.com